Isekai Yakkyoku

4 respostas neste tópico
[Imagem: XSFhbj3.png]

Ficha técnica:

Título: Isekai Yakkyoku
Título alternativo: Sinônimo: - | Japonês: 異世界薬局 | Abreviatura: -
Formato: Série de TV
Gênero: -
Obra original: Light Novel
Público-alvo da obra original: -
Editora (Label): -
Escrito por: Takayama Rizu
Site oficial:
Estúdio: Diomedea
Produtora: -
Diretor: Kusakawa Keizou
Supervisor do script: Watari Wataru
Character designer: Matsumoto Mayuko
Data de estréia: 07/2022
Número de episódios: -
Abertura: "Musouteki Chronicle" por Ishihara Kaori
Encerramento: "Hakuu" por Little Black Dress
Maiores informações: [Wikipedia (EN) | Wikipedia (PT) | MyAnimeList | AnimeNewsNetwork | AniDB]

Sinopse MAL:  After losing his little sister to an incurable disease, world-famous medical researcher Kanji Yakutani gave it his all to cure patients by dedicating his life to inventing new medicines. After working himself to death at the age of 31, the former pharmacist wakes up as a 10-year-old child whose body has been struck by lightning. He discovers that he has been reincarnated into a medieval world as Falma, a child of the respected De Médicis family. In a world where divine arts—magic granted through blessings from guardian deities—exist, Falma realizes that his body is host to the guardian deity of medicine. The boy has been granted the mythical divine arts of creation and reduction as well as the ability to instantly diagnose illnesses in people's bodies. He soon discovers the terrible state of medicine in this world: only nobles are able to afford medical care, which is ineffective at best and detrimental at worst. Using modern knowledge and his divine powers, Falma gradually makes a name for himself as a pharmacist despite his young age, even earning the recognition of the imperial court. When he finally acquires a proper pharmacy of his own, he sets out to pursue his goal of improving healthcare in the San Fleuve Empire and making it accessible to all. [Written by MAL Rewrite]
[Imagem: 80svwwx.jpg]
Começa em julho.
Trailer 2:


Usuários visualizando este tópico: 1 Visitantes